Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 5, 2005, Pages 463-470

  Brunner, M ^a   Vogelsang, H ^a   Greinwald, R ^b   Kletter, K ^a   Kvaternik, H ^c   Schrolnberger, C ^a   Eichler, H G ^a   Brunner, H ^d   Dudczak, R ^a   Muller M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Dr Falk Pharma GmbH   (Germany)

^c ARC SEIBERSDORF RESEARCH GMBH   (Austria)

^d GENERAL HOSPITAL LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BUDENOFALK; BUDESONIDE; ENEMA; TECHNETIUM 99M;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLON DISEASE; COLONOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOAM; GAMMA SCINTIGRAPHY; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROCTOSIGMOIDITIS; SIDE EFFECT; TISSUE LEVEL; ULCERATIVE COLITIS;

ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS, ULCERATIVE; COLON; FEMALE; GAMMA CAMERAS; HUMANS; MALE; PROCTOCOLITIS; PROSPECTIVE STUDIES; TECHNETIUM;

EID: 24344504167     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02571.x     Document Type: Article

References (32)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
2. Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J 2004; 80: 206-13.
3. Regueiro MD. Diagnosis and treatment of ulcerative proctitis. J Clin Gastroenterol 2004; 38: 733-40.
4. Bar-Meir S, Fidder HH, Faszczyk M, et al. International Budesonide Study Group. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Dis Colon Rectum 2003; 46: 929-36.
5. Danielsson A, Hellers G, Lyrenäs E, et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987; 22: 987-92.
6. Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol 1991; 26: 1225-30.
7. Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57: 267-79.
8. Lémann M, Galian A, Rutgeerts P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 557-62.
9. Bianchi Porro G, Prantera C, Campieri M, et al. Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. Eur J Gastroenterol Hepatol 1994; 6: 125-30.
10. Hammond A, Andus T, Gierend M, et al. German Budesonide Foam Study Group. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. Hepatogastroenterology 2004; 51: 1345-9.
11. Danielsson A, Löfberg R, Persson T, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992; 26: 1225-30.
12. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. US Budesonide Enema Study Group. Gastroenterology 1998; 115: 525-32.
13. Campieri M, Lanfranchi EA, Brignola C, et al. Retrograde spread of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Dis Colon Rectum 1986; 29: 108-10.
14. Ruddell W, Dickinson R, Dixon M, Axon A. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut 1980; 21: 885-9.
15. Gross V, Bar-Meir S, Lavy A, et al. Budesonide foam vs. budesonide enema in active ulcerative colitis. Gastroenterology 2004; 126 (4 Suppl. 2): A-465.
16. Somerville K, Langman M, Kane S, MacGilchrist A, Watkinson G, Salmon P. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone-21-phosphate enemas. Br Med J 1985; 291: 866.
17. Hay D, Sharma H, Irving M. Spread of steroid-containing foam after intrarectal administration. Br Med J 1979; 1: 1751-3.
18. Wood E, Wilson C, Hardy J. The spreading of foam and solution enemas. Int J Pharmacol 1985; 25: 191-7.
19. Campieri M, Corbelli C, Gionchetti P, et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992; 37: 1890-7.
20. Wilding IR, Kenyon CJ, Chauhan S, et al. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 161-6.
21. Wilding IR, Coupe AJ, Davis SS. The role of gamma-scintigraphy in oral drug delivery. Adv Drug Deliv Rev 2001; 46: 103-24.
22. Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-8.
23. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202.
24. Pabst G, Weimann HJ, Weber W. Lack of pharmacokinetic interactions between moxonidine and digoxin. Clin Pharmacokinet 1992; 23: 477-81.
25. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-76.
26. Campieri M, Paoluzi P, D'Albasio G, Brunetti G, Pera A, Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: a multicenter comparative trial with 5-ASA enema. Dig Dis Sci 1993; 38: 1843-50.
27. Dahlström K, Edsbäcker S, Kallen A. Rectal pharmacokinetics of budesonide. Eur J Clin Pharmacol 1996; 49: 293-8.
28. Danielsson A, Edsbäcker S, Löfberg R, et al. Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. Aliment Pharmacol Ther 1993; 7: 401-7.
29. Nyman-Pantelidis M, Nilsson A, Wagner ZG, Borga O. Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 617-22.
30. Lundin P, Naber T, Nilsson M, Edsbacker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. Aliment Pharmacol Ther 2001; 15: 45-51.
31. Möllmann HW, Hochhaus G, Tromm A, et al. Pharmacokinetics and pharmacodynamics of budesonide pH-modified release capsules. In: Möllmann, HW, May, B, eds. International Falk Workshop - Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease - from Basic Principles to Rational Therapy. Dordrecht: Kluwer Academic Publishers, 1996: 107-20.
32. Miller-Larsson A, Gustafsson B, Persson CG, Brattsand R. Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat. Aliment Pharmacol Ther 2001; 15: 2019-25.